The ECHELON-2 trial, which enrolled newly diagnosed CD30+ PTCL patients—mainly sALCL, randomized to receive BV plus CHP (cyclophosphamide, doxorubicin, and prednisone) or CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone)—demonstrated significantly improved PFS and OS with the BV-CHP regimen [58,59]. Here, TNFRSF8 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.